Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PCTAIRE1
is distant relative of the cyclin-dependent kinase family that has been implicated in spermatogenesis and neuronal development, but it has not been studied in cancer. Here, we report that
PCTAIRE1
is expressed in prostate, breast, and cervical cancer cells, where its RNAi-mediated silencing causes growth inhibition with aberrant mitosis due to defects in centrosome dynamics.
PCTAIRE1
was not similarly involved in proliferation of nontransformed cells, including diploid human IMR-90 fibroblasts. Through yeast two-hybrid screening, we identified tumor suppressor p27 as a
PCTAIRE1
interactor. In vitro kinase assays showed
PCTAIRE1
phosphorylates p27 at Ser10.
PCTAIRE1
silencing modulated Ser10 phosphorylation on p27 and led to its accumulation in cancer cells but not in nontransformed cells. In a mouse xenograft model of PPC1
prostate cancer
, conditional silencing of
PCTAIRE1
restored p27 protein expression and suppressed tumor growth. Mechanistic studies in HeLa cells showed that
PCTAIRE1
phosphorylates p27 during the S and M phases of the cell cycle. Notably, p27 silencing was sufficient to rescue cells from mitotic arrest caused by
PCTAIRE1
silencing. Clinically,
PCTAIRE1
was highly expressed in primary breast and prostate tumors compared with adjacent normal epithelial tissues. Together our findings reveal an unexpected role for
PCTAIRE1
in regulating p27 stability, mitosis, and tumor growth, suggesting
PCTAIRE1
as a candidate cancer therapeutic target.
...
PMID:PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells. 2520 4
While
PCTAIRE1
/PCTK1/Cdk16 is overexpressed in malignant cells and is crucial in tumorigenesis, its function in apoptosis remains unclear. Here we investigated the role of
PCTAIRE1
in apoptosis, especially in the extrinsic cell death pathway. Gene-knockdown of
PCTAIRE1
sensitized
prostate cancer
PPC1 and Du145 cells, and breast cancer MDA-MB-468 cells to TNF-family cytokines, including TNF-related apoptosis-inducing ligand (TRAIL). Meanwhile,
PCTAIRE1
-knockdown did not sensitize non-malignant cells, including diploid fibroblasts IMR-90 and the immortalized prostate epithelial cell line 267B1.
PCTAIRE1
-knockdown did not up-regulate death receptor expression on the cell surface or affect caspase-8, FADD and FLIP expression levels.
PCTAIRE1
-knockdown did promote caspase-8 cleavage and RIPK1 degradation, while RIPK1 mRNA knockdown sensitized PPC1 cells to TNF-family cytokines. Furthermore, the kinase inhibitor SNS-032, which inhibits
PCTAIRE1
kinase activity, sensitized PPC1 cells to TRAIL-induced apoptosis. Together these results suggest that
PCTAIRE1
contributes to the resistance of cancer cell lines to apoptosis induced by TNF-family cytokines, which implies that
PCTAIRE1
inhibitors could have synergistic effects with TNF-family cytokines for cytodestruction of cancer cells.
...
PMID:PCTAIRE1-knockdown sensitizes cancer cells to TNF family cytokines. 2579 Apr 48